JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 2006;59:813-826; doi:10.1136/jcp.2005.033019
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cerroni, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cerroni, L
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Lymphoma
*Skin Cancer

MY APPROACH

Lymphoproliferative lesions of the skin

L Cerroni

Correspondence to:
L Cerroni
Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, A-8036 Graz, Austria;lorenzo.cerroni{at}meduni-graz.at
ABSTRACT
Diagnosis and differential diagnosis of cutaneous lymphoproliferative disorders is one of the most difficult areas in dermatopathology, and biopsies are often taken to rule out a cutaneous lymphoma in patients with "unclear" or "therapy-resistant" skin lesions. Histopathological features alone often enable a given case to be classified to a diagnostic group (eg, epidermotropic lymphomas), but seldom allow a definitive diagnosis to be made. Performing several biopsies from morphologically different lesions is suggested, especially in patients with suspicion of mycosis fungoides. Immunohistochemistry is often crucial for proper classification of the cases, but in some instances is not helpful (eg, early lesions of mycosis fungoides). Although molecular techniques provide new, powerful tools for diagnosing cutaneous lymphoproliferative disorders, results of molecular methods should always be interpreted with the clinicopathological features, keeping in mind the possibility of false positivity and false negativity. In many cases, a definitive diagnosis can be made only on careful correlation of the clinical with the histopathological, immunophenotypical and molecular features.


Abbreviations: ALCL, anaplastic CD30-positive large-cell lymphoma; EORTC, European Organization for Research and Treatment of Cancer; HTLV, human T cell lymphoma or leukaemia virus; LyP, lymphomatoid papulosis; PCFCL, primary cutaneous follicle centre lymphoma; PCMZL, primary cutaneous marginal zone B cell lymphoma; PCR, polymerase chain reaction; SPTCL, subcutaneous panniculitis-like T cell lymphoma; TIA, T cell intracellular antigen; TdT, terminal deoxynucleotidyl transferase; WHO, World Health Organization




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
M Lira, A A Schenka, L A Magna, A C Cotta, M L Cintra, E M de Souza, P Brousset, and J Vassallo
Diagnostic value of combining immunostaining for CD3 and nuclear morphometry in mycosis fungoides
J. Clin. Pathol., February 1, 2008; 61(2): 209 - 212.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.